Table 3.
Calculation results of base cases. Standard deviations are shown in parentheses
| MSM-dg | MSM-kf | |||
|---|---|---|---|---|
| Immunosuppressant therapy | Control | Immunosuppressant therapy | Control | |
| Life years (years) | 76.35 (± 12.44) | 73.89 (± 12.14) | 78.80 (± 12.62) | 75.80 (± 12.82) |
| Utility (years) | 20.34 (± 4.08) | 19.43 (± 4.06) | 21.12 (± 4.08) | 20.00 (± 4.33) |
| Cost (1000 USD) | 199.98 (± 298.13) | 286.85 (± 350.27) | 122.99 (± 265.59) | 213.42 (± 365.60) |
| V0 (1000 USD) | 86.87 | 90.43 | ||
| V1 (1000 USD) | 132.29 | 146.25 | ||
MSM-dg Disease grade-based microsimulation, MSM-kf Kidney function-based microsimulation, V0 boundary below which the intervention is dominant; V1 boundary below which the intervention is cost-effective. V0 and V1 are defined in the main text